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Abstract 
The purine nucleoside phosphorylase gene (PNP) 
encodes an enzyme which reversibly catalyzes the 
phosphorolysis of purine nucleosides. PNP is 
ubiquitously expressed in mammalian cells and 
tissues. PNP mutations cause nucleoside 
phosphorylase deficiency which result in defective T 
cell mediated immunity but can also affect B cell 
immunity and antibody responses. 
Keywords 
Purine nucleotide phosphorylase (PNP), purine 
metabolism, PNP deficiency, Immunodeficiency, 
cancer. 
Identity 
Other names 
NP (Nucleoside Phosphorylase), PUNP, PRO1837 
HGNC (Hugo) 
PNP 
Location 
14q11.2 
Location (base pair) 
The gene can be found on chromosome 14 at 
location: chr14:20,469,379-20,477,094; spans 7,716 
bp. (according to UCSC, GRCh38/hg38) 
Figure 1. Genomic location of PNP (Chromosome 14 - NC_000014.9 Reference GRCh38.p7 Primary Assembly) 
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DNA/RNA 
The PNP gene is 7,716 bp long (according to UCSC, 
GRCh38/hg38), located on the plus strandand spans 
6 exons (NCBI Homo sapiens Annotation Release 
108). 
Transcription 
The gene has 8 transcripts (Table 1)  
 
 
Table 1. Transcripts of human PNP gene  (Ensemble, GRCh38.p10). 
Name   Transcript ID bp   Protein (aa)  Biotype 
PNP-201   ENST00000361505.9  1509 289  Protein coding 
PNP-203   ENST00000553591.1  770 221  Protein coding 
PNP-202   ENST00000553418.5 557 93  Protein coding 
PNP-205   ENST00000554065.1 554 61  Protein coding 
PNP-207   ENST00000556754.1  2573   Retained intron 
PNP-204   ENST00000554056.5 1635   Retained intron 
PNP-206   ENST00000556293.5  1023   Retained intron 
PNP-208   ENST00000557229.5  992   Retained intron 
 
Pseudogene 
A pseudogene has been identified on chromosome 2 
(NCBI Homo sapiens Annotation Release 108). 
Protein 
PNP encodes purine nucleoside phosphorylase (EC 
2.4.2.1) (NCBI Homo sapiens Annotation Release 
108). Mammalian PNPs are homotrimers with a 
monomeric molecular mass of about 31 kDa, each 
with a substrate-binding site (Figure 2) (Ting et al., 
2004; Aust et al., 1992). 
Expression 
PNP is ubiquitously expressed in human cells and 
tissues, but the highest activity is found in the 
peripheral red blood cells, blood granulocytes and 
lymphoid tissue (Roberts et al., 2004). 
Localisation 
PNP is present in both the cytosol and the 
mitochondria (Roberts et al., 2004). 
 
Figure 2. Structure of human purine nucleoside 
phosphorylase.  Structure of human PNP 
determined using X-ray diffraction (PDB ID: 3BGS) 
(Rinaldo-Matthis et al., 2008). 
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Figure 3. Enzymatic pathways involved in the degradation of purine nucleosides.  Thermodynamically, the 
equilibrium of the reaction is shifted in favor of nucleoside synthesis. However, phosphorolysis is highly favored 
over nucleoside synthesis, due to coupling with two additional enzymatic reactions: (1) oxidation and (2) 
phosphoribosylation of the liberated purine bases by xanthine oxidase (Xox) and hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT), respectively (modified from Giuliani et al., 2016). 
Function 
The PNP catalyzes the reversible phosphorolysis of 
purine nucleosides (primarily inosine and guanosine 
in humans) to generate the corresponding purine 
base and ribose 1-phosphate inosine in the presence 
of inorganic orthophosphate (Pi) (Jonsson et al., 
1992; Furihata et al., 2014). PNP is a ubiquitous 
enzyme of purine metabolism that functions in the 
salvage pathway, thus enabling the cells to 
synthesize purine nucleotides from purine bases by 
avoiding the ex-novo synthesis which is 
energetically expensive (Figure 3). Under normal 
conditions, phosphorolysis is favored due to the 
coupling of the PNP reaction with either purine base 
oxidation by xanthine oxidase or purine base  
 
 
phosphoribosylation by hypoxanthine-guanine 
phosphoribosyl transferase (HGPRT). On the other 
hand, nucleoside synthesis is thermodynamically 
favored over phosphorolysis (Erion et al., 1997; 
Bzowska et al., 2000). 
PNP activity is crucial for cell survival and function. 
PNP deficiency results in the accumulation of its 
substrates: inosine, deoxyinosine, guanosine, and 
deoxyguanosine. Increased phosphorylation of 
deoxyguanosine leads to dGTP accumulation, a 
potent feedback inhibitor of human ribonucleotide 
reductase. dGTP accumulation can also interfere 
with DNA synthesis or repair directly (Arpaia et al., 
2000; Ghodke-Puranik et al., 2017) (Figure 4). 
Abnormal activity of the enzyme is associated with 
different pathologies (Giuliani et al., 2016). 
 
Figure 4. PNP in the degradation and salvage pathways of purine nucleosides.  Phosphorolysis of the 
products of the ADA reaction, inosine and deoxyinosine, is catalyzed by PNP to yield hypoxanthine and ribose-
1-phosphate. Of the four PNP substrates, only deoxyguanosine is phosphorylated by the mitochondrial 
deoxyguanosine kinase (dGK). Further phosphorylation of dGMP results in the accumulation of dGTP, which 
interferes with DNA synthesis or DNA repair directly or inhibits ribonucleotide reductase activity. The PNP 
product guanine is salvaged back to the guanine nucleotide pools by HGPRT activity (modified from Arpaia et 
al., 2000). 
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Homology 
PNP enzyme has been isolated isolated from 
different species, including bacteria, protozoa, 
rodents, and mammals. A high degree of homology 
is found between these PNP enzymes, with human 
and bovine and murine PNPs demonstrating more 
than 87% and 84% homology, respectively (Ochs et 
al., 2013) (Figure 5). 
 
Figure 5. Pairwise alignment of PNP gene and PNP protein sequences (in distance from human)  
(HomoloGene, NCBI). 
Mutations 
PNP deficiency is caused by PNP gene mutations. 
As mentioned before, PNP contains six exons. Exon 
skipping, missense, and frameshift mutations in 
these six exons have been found to cause PNP 
deficiency, and the most frequent mutations are the 
substitution of A to C or A to G  at cDNA position 
58 or 234, respectively (Brodszki et al., 2015). Up-
to-date and comprehensive list of PNP associated 
mutations was given in Table 2. Furthermore, it 
should be also considered that PNP polymorphisms 
might be associated with variability in the clinical 
presentation and course of affected patients 
(Moallem et al., 2002).  
 
 
Table 2. Purine nucleoside phosphorylase (PNP) deficiency related mutations.  
# Location Mutation Protein Reference 
[1] Exon 2 c.59A>C p.20H>P Yeates et al., 2017 
[2] Exon 2 c.70C>T p.Arg24X Walker et al., 2011 
[3] Exon 2 c.172C>T p.Arg57X Walker et al., 2011 
[4] Exon 2 c.181G>T p.Tyr5AlafsX28 Walker et al., 2011 
[5] Exon 3 c.199C>T p.Arg67X Walker et al., 2011 
[6] Exon 3 c.212G>A p.71Gly>Glu Walker et al., 2011 
[7] Exon 3 c.257A>G p.86His>Arg Walker et al., 2011 
[8] Exon 3 c.265G>A p.89Glu>Lys Walker et al., 2011 
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[9] Exon 4 c.349G>A p.117Ala>Thr Grunebaum et al., 2004 
[10] Exon 4 c.383A>G p.128Asp>Gly Walker et al., 2011 
[11] Exon 4 c.385 387delATC p.Ile129del Walker et al., 2011 
[12] Exon 4 c.437C>T p.146Pro>Leu Alangari et al., 2009 
[13] Exon 5 c.467G>C p.156Gly>Ala Moallem et al., 2002 
[14] Exon 5 c.475T>G p.159Phe>Val Walker et al., 2011 
[15] Exon 5 c.487T>C p.163Ser>Pro Al-Saud et al., 2009 
[16] Exon 5 c.520G>C p.174Ala>Pro Walker et al., 2011 
[17] Exon 5 c.569G>T p.190Gly>Val Walker et al., 2011 
[18] Exon 5 c.575A>G p.192Tyr>Cys Walker et al., 2011 
[19] Exon 6 c.700C>G p.Arg234X Walker et al., 2011 
[20] Exon 6 c.701G>C p.234Arg>Pro Walker et al., 2011 
[21] Exon 6 c.729C>G p.Asn243Lys Brodszki et al., 2015 
[22] Exon 6 c.730delA p.Lys244ArgfsX17 Walker et al., 2011 
[23] Exon 6 .746A>C p.Tyr249Cys Brodszki et al., 2015 
[25] Exon 6 c.770A>G p.257His>Arg Walker et al., 2011 
[26] Intron 3 c.285+1G>A p.Val61GlyfsX30 Walker et al., 2011 
Implicated in 
Associated Pathologies   
 
When PNP is defective, dGTP accumulation inhibits 
DNA replication and mitochondrial DNA repair 
which cause increased sensitivity of T lymphocytes 
to DNA damage and apoptosis during thymus 
selection. In addition, the lack of DNA replication is 
critical especially in the immune system: PNP 
deficiency leads to S-phase block in 7-11% of 
circulating lymphocytes. Mutations leading to PNP 
deficiency result in an autosomal recessive disorder 
known as severe combined immune deficiency 
(SCID) characterized by a profound deficiency in T 
cell function with variable B cell involvement. PNP 
deficiency is a very rare autosomal recessive 
condition, accounting for approximately 4% of all 
SCID cases (Madkaikar et al., 2011; Ghodke-
Puranik et al., 2017). Small hypoplastic thymus, 
reduced T lymphocytes in peripheral blood, 
abnormal response of T lymphocytes to stimulation, 
and enlarged spleen are found in most PNP-deficient 
patients (Toro and Grunebaum, 2006). 
Lymphopenia, reduced serum uric acid, and 
abnormal PNP enzymatic activity assist in the 
diagnosis of PNP deficiency. Patients with SCID 
lack virtually all immune protection from foreign 
invaders such as bacteria, viruses, and fungi, 
therefore they are prone to repeated and persistent 
infections that can be very detrimental and life 
threatening. About two-thirds of individuals with 
PNP deficiency have neurological problems, 
including hypertonia, spasticity, tremors, ataxia, 
retarded motor development, behavioral difficulties, 
and varying degrees of mental retardation. People 
with PNP deficiency are also at increased risk of 
developing autoimmune disorders (autoimmune 
hemolytic anemia, idiopathic thrombocytopenic 
purpura-ITP, autoimmune neutropenia, thyroiditis, 
and lupus). Infants with SCID typically grow much 
more slowly than healthy children and experience 
pneumonia, chronic diarrhea, and widespread skin 
rashes. Without successful treatment to restore 
immune function, children with SCID usually live 
only into early childhood. Lymphoma and 
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lymphosarcoma have also been reported in children 
with PNP immunodeficiency (Ghodke-Puranik et 
al., 2017; Arpaia et al., 2000).  
 
On the other hand, PNP levels are significantly 
upregulated in several tumor cells (Figure 6). In 
comparison with healthy individuals, PNP activity 
was shown to be higher in lymphocytes of patients 
suffering from bronchogenic carcinoma (Gierek et 
al., 1987; Rendeková et al., 1983). Sanfilippo et al. 
claimed a relationship between tissue PNP and 
tumor invasiveness in human colon carcinoma 
(Sanfilippo et al., 1994). Furthermore, Roberts et al. 
showed that plasma PNP activity was higher also in 
patients with breast, gastric, colon, lung and ovarian 
cancers and lymphoma (Roberts et al., 2004). From 
the biomarker perspective, Vareed et al. found that 
PNP levels were higher in sera from pancreatic 
adenocarcinoma patients and levels of PNP-
regulated metabolites in serum, guanosine and 
adenosine, were suitable to determine pancreatic 
adenocarcinoma and distinguish pancreatic 
adenocarcinoma from benign tumors (Vareed et al., 
2011). Plasma PNP activity was also higher in 
patients with asthma than in either healthy subjects 
or patients with gout (Yamamoto et al., 1995). 
However, a low level of PNP activity was found in 
mononuclear cells from patients with acute myeloid 
and lymphoblastic leukemia and with chronic 
lymphocytic leukemia (Morisaki et al., 1986).  
 
 Treatment 
Bone marrow transplantation in PNP deficiency has 
been attempted with variable degree of success. 
However, HLA-matched donors are not readily 
available, and transplants using HLA incompatible 
donors are frequently result in procedure-related 
morbidity, graft-versus-host disease or graft loss 
(Liao et al., 2008). Myers et al. suggested umbilical 
cord blood, a readily available and pathogen-free 
source of stem cells, transplantation as a treatment 
option for patients with PNP deficiency who do not 
have a HLA-matched donor (Myers et al., 2004).  
 
Gene therapy with autologous cells, either total bone 
marrow (BM) or hematopoietic stem cells (HSCs) 
isolated from the BM, transduced with the normal 
gene sequence that can express the missing protein 
represents an attractive option for inherited 
hematological and immunological defects, including 
PNP deficiency (Liao et al., 2008). In in vitro, 
Foresman et al. showed that retroviral-mediated PNP 
gene transfer and expression correct the metabolic 
defects caused by PNP deficiency in murine 
lymphoid cells (Foresman et al., 1992). In PNP -/- 
mouse model, PNP deficiency was corrected by 
transplanting BM cells which have been transduced 
with lentiviral vectors containing the human PNP 
gene (lentiPNP) (Liao et al., 2008). However, 12 
weeks after transplant, benefit of lentiPNP 
transduced cells decreased, which indicates that an 
improved gene expression strategy is required to 
afford a successful gene therapy for PNP deficiency 
(Liao et al., 2008). Indeed, PNP enzyme replacement 
therapy has been evaluated in PNP -/- mice by 
administration of PNP fused trans-activator of 
transcription (TAT) protein (TAT-PNP). TAT 
induced rapid and efficient delivery of active PNP 
into many tissues, including the brain, and TAT-PNP 
remained effective over 24 weeks post-treatment, 
and corrected metabolic abnormalities and 
immunodeficiency, and extended survival (Toro and 
Grunebaum, 2006). Similarly, PNP fused with 
protein transduction domain (PTD) from TAT 
protein was found to rapidly enter PNP deficient 
lymphocytes and increase intracellular enzyme 
activity for 96 h, and correct abnormal functions of 
PNP deficient lymphocytes including their response 
to stimulation and IL-2 secretion, in vitro (Toro et 
al., 2006). These results show that fusion protein 
approach for PNP deficiency is an attractive and 
promising method for intracellular delivery of PNP.  
 
Since PNP deficiency results in selective cellular 
immunodeficiency, PNP inhibitors are considered to 
be potentially effective suppressors of T cell 
proliferative diseases, such as T cell lymphoma and 
T cell related autoimmune diseases, and may also be 
useful for the suppression of the graft-versus-host 
reaction (Ting et al., 2004). In addition, PNP 
inhibitors have shown to be promising based on their 
ability to potentiate the in vivo activity of antiviral 
and anticancer drugs (Erion et al., 1997). As an 
enzyme prodrug model, Krais et al. generated a 
fusion protein called as PNP-AV which is composed 
of E. coli PNP and human annexin V (AV). AV 
binds to phosphatidylserine (PS) expressed 
externally on tumor cells and endothelial cells of 
tumor vasculature, but not normal vascular 
endothelial cells. In in vitro, the recombinant fusion 
protein of PNP-AV was shown to bind and kill breast 
cancer and endothelial cells when used in the 
enzyme prodrug therapy with fludarabine. Krais et 
al. proposed that this approach allows for systemic 
administration of the fusion protein, with targeted 
accumulation of PNP in the tumor. After clearance 
of PNP-AV from the bloodstream, fludarabine, the 
substrate of E. coli PNP, can be administered 
systemically, so that 2-fluoroadenine is generated at 
the surface of the endothelial cells lining the tumor 
vasculature. This freely diffusible molecule is able to 
enter the cell and inhibit protein, RNA, and DNA 
synthesis in endothelial cell of tumor blood vessel. 
Since fludarabine is not a substrate of human PNP, 
the conversion of fludarabine to 2-fluoroadenine will 
not occur in normal tissue. Therefore, authors 
suggested that this strategy can be successful as a 
targeted therapy for breast cancer (Krais et al., 2013). 
More recently, phase I dose-escalating trial of E. coli 
PNP-fludarabine treatment was demonstrated to be 
PNP (Purine Nucleoside Phosphorylase)  
 
Atlas Genet Cytogenet Oncol Haematol. 2018; 22(11) 437 
 
safe and effective in head and neck squamous cell 
carcinoma, adenoid cystic carcinoma and melanoma. 
Successful regression of tumors without significant 
toxicity was shown in this first-in-human study of an 
effective prodrug activation strategy using E. coli 
PNP (Rosenthal et al., 2015). 
 
Figure 6. PNP expression in primary tumors. Normalized gene expression data of RNASeqV2 which 
was extracted from TCGA using R package TCGA-Assembler (t test, adjusted p<0.05, using Benjamini-
Hochberg FDR, data obtained from https://bioinfo.uth.edu). 
Lymphoma, Bronchogenic 
carcinoma, Colon carcinoma, Breast 
cancer, Gastric cancer, Lung cancer, 
Ovarian cancer, Pancreatic 
adenocarcinoma 
PNP activity was found higher in patients with 
indicated cancer types compared to  control groups 
(Roberts et al., 2004; Rendeková et al., 1983; 
Sanfilippo et al., 1994; Vareed et al., 2011). 
Acute myeloid leukemia, 
Lymphoblastic leukemia, Chronic 
lymphocytic leukemia 
A low level of PNP activity was found in 
mononuclear cells from patients with acute myeloid 
and lymphoblastic leukemia and with chronic 
lymphocytic leukemia (Morisaki et al., 1986). 
Severe Combined Immune Deficiency 
(SCID) 
PNP deficiency is an autosomal recessive enzyme 
disorder, engaged in four percent of SCID cases in 
humans (Pannicke et al., 1996). 
Asthma 
PNP activity was higher in patients with asthma than 
in either healthy subjects or patients with gout 
(Yamamoto et al., 1995). 
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